Project Overview: Nicotinamide Adenine Dinucleotide (NAD+)
Research investigating intravenous Nicotinamide Adenine Dinucleotide (NAD+) has demonstrated promise as an effective revitalizing agent for increasing energy levels and physical strength in clinical outpatients suffering from chronic pain and fatigue. The following abstract provides insight into a preliminary pilot study assessing the clinical application of Brain Restorative (BR) NAD+ IV as a potential treatment modality for illnesses of the immune and nervous system.
Project Details
RESEARCH NAME: Administration of IV infusions of BR+/NAD+ alleviates psychological disorders and chronic pain symptoms associated with Postural Orthostatic Tachycardia Syndrome (POTS), Chronic Fatigue Syndrome, and Heavy Metal Poisoning.
CATEGORY: Pain Management
DELIVERY MODE: Intravenous
DURATION: TBD
LOCATION: New York, USA.
Treatment Trials:
Selected patients underwent a 3-5 hour treatment with BR+/NAD+ IV infusions at a concentration of 50 mg/ml. They also took oral mineral support tablets and NAD+ cell regeneration capsules. Throughout the infusion, patients’ heart rate and blood oxygen saturation levels were monitored using pulse oximeters. The study aims to assess how this therapy can help improve the health and well-being of individuals presenting with Postural orthostatic tachycardia syndrome (POTS), Chronic Fatigue Syndrome (CFS) and Heavy Metal Poisoning (HMP).